logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

About bluebird bio

bluebird bio bluebird bio ( BLUE ) financial results and business highlights for the third quarter 2020 are important to be aware of when volatility and negative analysis lack common sense. The stock selloff has been steady and progressive while...

Read More

November 10, 2020

0

Court Upholds Validity of Amgen's Claims Regarding Enbrel

Press Release Amgen Wins Patent Case On Enbrel® (etanercept) Court Upholds Validity of Patent Claims Directed to Enbrel Preliminary Injunction to Remain in Place THOUSAND OAKS, Calif., Aug. 9, 2019 , /PRNewswire/ --  Amgen ( AMGN ) today announced that the U.S. District...

Read More

August 9, 2019

0

A Press Release About Regeneron Product REGN-EB3 Showing Superiority in Preventing Ebola Deaths

Palm Ebola Clinical Trial Stopped Early as Regeneron Product REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths TARRYTOWN, N.Y., Aug. 12, 2019,/PRNewswire/ --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the Company was informed by study...

Read More

August 13, 2019

0

Moderna News. See Also: Regeneron Antibody Cocktail Could Reach the Market in October

SARS-CoV-2 Virus Vaccines Moderna On Monday Moderna ( MRNA ) started its Phase 3 clinical trial on 30,000 people with its product mRNA-1273. Separately, in a press release Moderna announced a preclinical study evaluating its product mRNA-1273 has been published in...

Read More

July 29, 2020

0

PTC Therapeutics' Many Attractive Achievements and Approvals

PTC Therapeutics Approvals and Achievements PTC Therapeutics ( PTCT ) has achieved a lot recently. The latest is the August approval from the U.S. FDA of its product Evrysdi (risdiplam), the first orally administered at-home treatment for spinal muscular atrophy...

Read More

November 18, 2020

0

Pfizer and BioNTech Submitted an EUA to the FDA for their COVID-19 Vaccine, BNT162b2

Pfizer, BioNTech & Moderna When asked whether we heard the news about the submission of the Emergency Use Authorization (EUA) and whether we will inform our readers about it. Our answer was that we have posted many articles about Pfizer's...

Read More

November 21, 2020

0

Compugen: A Stock To Keep

Compugen Compugen ( CGEN ) cancer immunotherapy’s predictive target computational discovery platforms enabled it to identify two checkpoint proteins, PVRIG and TIGIT, when nobody else could. Compugen’s technological capability has also enabled it to create therapeutic inhibitors of its two...

Read More

August 3, 2020

0

Regeneron Granted FDA Emergency Use Authorization for its COVID-19 Antibody Cocktail Therapy

Regeneron Pharmaceuticals Receives EUA from the FDA for REGEN-COV2 Regeneron Pharmaceuticals’ ( REGN ) antibody cocktail therapy casirivimab and imdevimab, known also REGN-COV2 or REGEN-COV2 , received Emergency Use Authorization ( EUA ) from the U.S. Food and Drug Administration...

Read More

November 22, 2020

0

Seres Therapeutics Oral Microbiome Product SER-109 Meets Trial Endpoint

Seres Therapeutics Oral Microbiome Product SER-109 for Recurrent C. Difficile Infection Meets Trial Endpoint SER-109 demonstrated a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared to placebo. Efficacy results Support BLA filing as...

Read More

August 10, 2020

0

Moderna's Investigational Zika Vaccine Is Granted FDA Fast Track Designation

From Moderna  From the press release we learned that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track designation for Moderna   ( MRNA ) investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1...

Read More

August 20, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 10
  • 11
  • 12
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy